Gilead Partners for Global Access to Generic Lenacapavir in 120 Countries

Gilead Sciences has entered into royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to produce and distribute generic lenacapavir in 120 low- and lower-middle-income countries. This initiative, subject to regulatory approval, aims to make lenacapavir widely available for HIV prevention and treatment, particularly in resource-limited settings with high HIV incidence. Gilead’s strategy includes providing its product at no profit until the licensed manufacturers can fully meet demand. The selected partners— Dr. Reddy’s, Emcure, Eva Pharma, Ferozsons, Hetero, and Mylan—were chosen for their expertise in sterile injectable medicines and HIV treatments.

The licensing agreements cover both lenacapavir for HIV prevention (pending approval) and for the treatment of heavily treatment-experienced adults with multi-drug-resistant HIV. Gilead hopes that by partnering with high-volume generic manufacturers early, they can ensure rapid access to lenacapavir once it's approved, especially where the need is greatest. The collaboration underscores Gilead's broader commitment to ending the global HIV epidemic by increasing access to innovative therapies for everyone, everywhere.

Daniel O’Day, CEO of Gilead, emphasized that these agreements reflect the company’s goal to make lenacapavir accessible to patients in need as quickly and broadly as possible.